Abstract:Background: Natural killer T-cell lymphoma (NKTCL) is a highly aggressive non-Hodgkin lymphoma with more incidence in Asian and South American populations. Patients suffered from advanced stage disease have limited treatment options and dismal prognosis. Therefore, the development of novel therapeutic targets for the treatment of this debilitating disease is urgently needed. ITK (interleukin-2-inducible kinase, ITK), one of the Tec kinase family, is predominantly expressed in T and natural killer T cells. Though redundant ITK expression was reported in NKTCL, the role of ITK in NKTCL has not been fully investigated. In this study, we elucidate the important role of ITK within the pathogenesis of NK/T cell lymphoma. Methods: Expression level of ITK and p-ITK in NKTCL cell line and patients were performed by immunoblotting and immunohistochemistry, respectively. The lentivirus containing dox-induced ITK targeting shRNA or ITK overexpression plasmid were used to mediate conditional ITK knockdown or stable overexpression of ITK. NKTCL cell line stably transfected dox-induced shRNA or control shRNA plasmids was engrafted in opposite lateral of the same NCG mice to investigate the effect of ITK knockdown in vivo, 4 mg/mL dox in drinking water was administrated to induce ITK knockdown in vivo. The cell viability of tumor cells was analyzed through Cell Titer-Glo® Luminescent Cell Viability Assay. Soft agarose colony forming assay was employed to determine the influence of ITK inhibitor on colony-forming ability of NKTCL cell lines. Results: The expression level of ITK were first analyzed in NKTCL cell lines (KHYG-1, YT, NK-YS and YTS). The KHYG-1 and YT cell showed high level of phosphorylation of ITK activation. Meanwhile, the activation and expression of ITK protein could also be observed in NKTCL patients (n = 17). Next the ITK overexpression plasmid were transfected into NK-YS and YTS cells, which promoted the proliferation of tumor cells. On the other hand, the conditional knockdown of ITK significantly suppressed the growth of KHYG-1 and YT cells. Furthermore, in vivo ablation of ITK in YT mouse model obviously delayed the progression of NKTCL tumors, showing smaller tumor size and lower weight compared with control group, highlighting ITK is a new fragility of NKTCL cells. To further validate this therapeutic effect, NKTCL cells were treated with ITK inhibitors for 24h, 48h and 72h in vitro, The ITK inhibitors repressed the viability of these NKTCL cells in a concentration and time-dependent manner. Furthermore, ITK inhibitors treatment abolished the colony formation of NKTCL cells, which indicated the ITK might represent the potential therapeutic target for NKT cell lymphoma. Taking together, targeting ITK is a promising strategy for treatment NKTCL. Encore Abstract - previously submitted to regional or national meetings (up to <1’000 attendees) Keywords: Aggressive T-cell non-Hodgkin lymphoma, Molecular Targeted Therapies No conflicts of interests pertinent to the abstract.

Synthesis and Characterization of Soquelitinib a Selective ITK Inhibitor That Modulates Tumor Immunity

Dynamic Single-Cell Profiling Reveals Novel Immune Regulatory Mechanism of ITK Inhibitor Soquelitinib in Refractory T Cell Lymphoma

Abstract 1813: Selective ITK blockade induces antitumor responses and enhances efficacy to immune checkpoint inhibitors in preclinical models

ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas

Discovery of Potent and Highly Selective Interleukin-2-Inducible T-Cell Kinase Degraders with in Vivo Activity.

Design, synthesis, and biological evaluation of novel azaspirooxindolinone derivatives as potent inhibitors of ITK and BTK-positive cancers

Itk Inhibitor Induces Th1 Skewing and Host Anti‐tumor Response Mediated by CD8+ TEMRA Cells in Refractory T Cell Lymphoma Patients

Discovery of potent inhibitors for interleukin-2-inducible T-cell kinase: structure-based virtual screening and molecular dynamics simulation approaches

ITK Inhibition Induced in Vitro and in Vivo Anti-Tumor Activity Through Downregulating TCR Signaling Pathway in Malignant T Cell Lymphoma

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

The Novel Role of the Tyrosine Kinase Inhibitor Sunitinib on Control of Myeloid-Derived Suppressor Cell Function and T-Regulatory Cell to Th17/Th1 Conversion

A Novel Multikinase Inhibitor R8 Exhibits Potent Inhibition on Cancer Cells Through Both Apoptosis and Autophagic Cell Death

A Novel Selective Axl/Mer/CSF1R Kinase Inhibitor as a Cancer Immunotherapeutic Agent Targeting Both Immune and Tumor Cells in the Tumor Microenvironment

Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases

Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease

Design, Synthesis and Structure–activity Relationship of Indolylindazoles As Potent and Selective Covalent Inhibitors of Interleukin-2 Inducible T-cell Kinase (ITK)

Interleukin‐2‐inducible kinase represents a novel therapeutic target for NK/T‐cell lymphoma treatment

Discovery and Optimization of Indazoles As Potent and Selective Interleukin-2 Inducible T Cell Kinase (itk) Inhibitors

A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity

Structure-Based Design and Synthesis of Potent Benzothiazole Inhibitors of Interleukin-2 Inducible T Cell Kinase (Itk)